NCT01874561 - Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

January 31, 2014

Conditions

Cardiac Conduction and Repolarization

Interventions

DRUG

Custirsen

Custirsen will be administered iv using an infusion pump over a 2-hour period.

DRUG

Placebo

Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.

DRUG

Moxifloxacin

Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.

Trial Locations (1)

Teva Investigational Site 10565, Lenexa